A trial in the Netherlands in which paroxetine was compared with placebo in patients who were all repeaters of self-harm but who did not suffer from current depressive disorder showed apparent benefits for a subgroup of patients who received paroxetine, namely
those who had a history of between one and four episodes of self-harm. Patients with a history of five or more episodes did not seem to benefit.
(21) The findings of this study are clearly of interest (although
post hoc subgroup analyses of this kind must be treated with caution). Recently there has been much attention to the risk of antidepressants increasing suicidal ideation and acts in adolescents.
(22) Also, it has become clear that there is increased risk with all types of antidepressants during the initial period of treatment.
(23) These findings have highlighted the need to be cautious in the use of antidepressants, to provide early follow-up after initiating therapy, and to consider combining antidepressant treatment with other therapies, especially for adolescents (in whom only fluoxetine is currently recommended for the treatment of depression).